Lyra Therapeutics (LYRA) Competitors $0.26 -0.02 (-7.17%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends LYRA vs. PYPD, PAVM, DRIO, STIM, APT, LNSR, NTRB, NSPR, BLAC, and MLSSShould you be buying Lyra Therapeutics stock or one of its competitors? The main competitors of Lyra Therapeutics include PolyPid (PYPD), PAVmed (PAVM), DarioHealth (DRIO), Neuronetics (STIM), Alpha Pro Tech (APT), LENSAR (LNSR), Nutriband (NTRB), InspireMD (NSPR), Bellevue Life Sciences Acquisition (BLAC), and Milestone Scientific (MLSS). These companies are all part of the "medical equipment" industry. Lyra Therapeutics vs. PolyPid PAVmed DarioHealth Neuronetics Alpha Pro Tech LENSAR Nutriband InspireMD Bellevue Life Sciences Acquisition Milestone Scientific Lyra Therapeutics (NASDAQ:LYRA) and PolyPid (NASDAQ:PYPD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, community ranking, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk. Do analysts rate LYRA or PYPD? Lyra Therapeutics presently has a consensus target price of $4.50, suggesting a potential upside of 1,638.12%. PolyPid has a consensus target price of $14.00, suggesting a potential upside of 324.24%. Given Lyra Therapeutics' higher possible upside, equities research analysts plainly believe Lyra Therapeutics is more favorable than PolyPid.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lyra Therapeutics 1 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00PolyPid 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer LYRA or PYPD? In the previous week, Lyra Therapeutics and Lyra Therapeutics both had 1 articles in the media. Lyra Therapeutics' average media sentiment score of 0.33 beat PolyPid's score of 0.00 indicating that Lyra Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lyra Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PolyPid 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals have more ownership in LYRA or PYPD? 95.6% of Lyra Therapeutics shares are held by institutional investors. Comparatively, 26.5% of PolyPid shares are held by institutional investors. 4.7% of Lyra Therapeutics shares are held by insiders. Comparatively, 24.7% of PolyPid shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has preferable valuation and earnings, LYRA or PYPD? PolyPid has lower revenue, but higher earnings than Lyra Therapeutics. PolyPid is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLyra Therapeutics$1.56M10.86-$62.68M-$1.58-0.16PolyPidN/AN/A-$23.86M-$9.99-0.33 Which has more volatility and risk, LYRA or PYPD? Lyra Therapeutics has a beta of -0.02, meaning that its share price is 102% less volatile than the S&P 500. Comparatively, PolyPid has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500. Does the MarketBeat Community favor LYRA or PYPD? PolyPid received 2 more outperform votes than Lyra Therapeutics when rated by MarketBeat users. Likewise, 76.47% of users gave PolyPid an outperform vote while only 60.00% of users gave Lyra Therapeutics an outperform vote. CompanyUnderperformOutperformLyra TherapeuticsOutperform Votes2460.00% Underperform Votes1640.00% PolyPidOutperform Votes2676.47% Underperform Votes823.53% Is LYRA or PYPD more profitable? PolyPid has a net margin of 0.00% compared to Lyra Therapeutics' net margin of -5,570.88%. Lyra Therapeutics' return on equity of -102.22% beat PolyPid's return on equity.Company Net Margins Return on Equity Return on Assets Lyra Therapeutics-5,570.88% -102.22% -57.77% PolyPid N/A -969.85%-121.65% SummaryLyra Therapeutics beats PolyPid on 8 of the 15 factors compared between the two stocks. Ad DarwinUnlock the Secret to Earning Consistent Income from Stocks Under $30!Are you ready to transform your investment strategy and generate a steady monthly income? We’re excited to offer you our exclusive report, "Options Trading Strategy: 2 (Surprisingly) Low-Cost Stocks Primed for Generating Monthly Income," FREE!👉 Yes, I Want the Free Report! 👈 Get Lyra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LYRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LYRA vs. The Competition Export to ExcelMetricLyra TherapeuticsSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.95M$4.43B$5.32B$8.52BDividend YieldN/A41.87%5.07%4.13%P/E Ratio-0.1641.93121.3415.54Price / Sales10.8660.941,497.9292.41Price / CashN/A48.8739.6734.18Price / Book0.174.294.755.07Net Income-$62.68M$11.84M$118.54M$225.38M7 Day Performance3.60%1.27%-0.39%0.07%1 Month Performance-0.04%2.09%6.05%3.93%1 Year Performance-91.22%33.66%38.13%32.51% Lyra Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LYRALyra Therapeutics3.1707 of 5 stars$0.26-7.2%$4.50+1,638.1%-91.2%$16.95M$1.56M-0.1650Upcoming EarningsPYPDPolyPid2.2833 of 5 stars$3.25-2.1%$14.00+330.8%-14.3%$15.60MN/A-0.3380PAVMPAVmed4.1685 of 5 stars$1.10+2.6%$21.00+1,812.6%-73.0%$11.43M$2.45M-0.1390Positive NewsGap UpDRIODarioHealth2.1471 of 5 stars$1.00+2.7%$4.00+301.6%-6.2%$29.80M$19.15M-0.84200Upcoming EarningsSTIMNeuronetics2.6182 of 5 stars$0.99+0.1%$4.67+370.8%-10.4%$30.04M$71.35M-0.88180Upcoming EarningsNews CoverageAPTAlpha Pro TechN/A$5.77-2.7%N/A+36.0%$67.45M$61.09M14.07120LNSRLENSAR2.7819 of 5 stars$5.60+5.7%$8.00+42.9%+150.2%$63.82M$45.12M-3.59110News CoverageNTRBNutriband0.5236 of 5 stars$5.78+0.7%N/A+163.6%$63.79M$1.80M-7.1410News CoverageGap DownNSPRInspireMD2.1033 of 5 stars$2.51+2.4%$4.50+79.3%-34.5%$62.57M$6.57M-3.3950Upcoming EarningsAnalyst ForecastBLACBellevue Life Sciences AcquisitionN/A$10.99+0.4%N/A+5.3%$61.80MN/A0.00N/APositive NewsMLSSMilestone Scientific2.5581 of 5 stars$0.78flat$1.25+60.3%-5.8%$60.24M$8.42M-11.1430Analyst ForecastNews Coverage Related Companies and Tools Related Companies PYPD Competitors PAVM Competitors DRIO Competitors STIM Competitors APT Competitors LNSR Competitors NTRB Competitors NSPR Competitors BLAC Competitors MLSS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LYRA) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LYRA Stock Alerts